•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Service Corp International (SCI) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100
Service Corporation Q2 Earnings on Deck: Factors to Watch for SCI
Service Corporation International Announces Schedule For Second Quarter 2026 Earnings Release and Conference Call
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
CEL-SCI Announces Closing of Offering
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
CEL-SCI Corporation Announces Pricing of Offering
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
SERVICE CORPORATION INTERNATIONAL INCREASES SHARE REPURCHASE AUTHORIZATION
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award
Service Corp. (SCI) Down 5.9% Since Last Earnings Report: Can It Rebound?
Service Corporation International: Still A 'Buy' For Long-Term Stability
CEL-SCI Reports Fiscal Second Quarter 2026 Results
Service Corporation International (SCI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CEL-SCI Announces Closing of Public Offering
CEL-SCI Corporation Announces Pricing of Public Offering
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
Service Corp Increases Dividend, Reflects Financial Strength